PT2632479T - Péptidos de fviii para indução de tolerância imunitária e imunodiagnóstico - Google Patents

Péptidos de fviii para indução de tolerância imunitária e imunodiagnóstico

Info

Publication number
PT2632479T
PT2632479T PT117968461T PT11796846T PT2632479T PT 2632479 T PT2632479 T PT 2632479T PT 117968461 T PT117968461 T PT 117968461T PT 11796846 T PT11796846 T PT 11796846T PT 2632479 T PT2632479 T PT 2632479T
Authority
PT
Portugal
Prior art keywords
immunodiagnostics
immune tolerance
tolerance induction
fviii peptides
fviii
Prior art date
Application number
PT117968461T
Other languages
English (en)
Portuguese (pt)
Inventor
Nora Steinitz Katharina
Maria Wilhelmina Van Helden Paula
Maria Reipert Birgit
Schwarz Hans-Peter
Ehrlich Hartmut
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of PT2632479T publication Critical patent/PT2632479T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
PT117968461T 2010-10-27 2011-10-27 Péptidos de fviii para indução de tolerância imunitária e imunodiagnóstico PT2632479T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40740210P 2010-10-27 2010-10-27
US201161467894P 2011-03-25 2011-03-25
US201161502476P 2011-06-29 2011-06-29

Publications (1)

Publication Number Publication Date
PT2632479T true PT2632479T (pt) 2017-07-24

Family

ID=45349271

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117968461T PT2632479T (pt) 2010-10-27 2011-10-27 Péptidos de fviii para indução de tolerância imunitária e imunodiagnóstico

Country Status (20)

Country Link
US (3) US8969524B2 (enExample)
EP (2) EP3260132B1 (enExample)
JP (2) JP6122780B2 (enExample)
KR (2) KR102040867B1 (enExample)
CN (2) CN103298482B (enExample)
AR (1) AR083586A1 (enExample)
AU (2) AU2011319747C1 (enExample)
BR (1) BR112013010362A2 (enExample)
CA (1) CA2815239C (enExample)
DK (1) DK2632479T3 (enExample)
EA (1) EA034494B1 (enExample)
ES (2) ES2912455T3 (enExample)
HK (1) HK1215442A1 (enExample)
MX (1) MX347805B (enExample)
NZ (2) NZ609474A (enExample)
PL (2) PL3260132T3 (enExample)
PT (1) PT2632479T (enExample)
SG (2) SG189914A1 (enExample)
TW (3) TW201730205A (enExample)
WO (1) WO2012058480A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
PL2917232T3 (pl) * 2012-11-12 2017-09-29 Apitope International Nv Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
EP2968499A4 (en) * 2013-03-15 2016-11-30 Haplomics Inc COMPOSITIONS AND METHODS FOR THE IMMUNO-TOLERANCE INDUCTION FOR FACTOR VIII SPATIAL THERAPIES IN PERSONS WITH HEMOPHILIA A
WO2015192101A1 (en) * 2014-06-12 2015-12-17 University Of Hawaii Uses of humanized cobra venom factor for reducing or preventing immunogenicity
CA2973529A1 (en) * 2015-01-26 2016-08-04 Cellectis Cll1-specific multi-chain chimeric antigen receptor
SG11201808475XA (en) 2016-04-15 2018-10-30 Baxalta Inc Method and apparatus for providing a pharmacokinetic drug dosing regiment
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538694A (ja) * 2002-04-18 2005-12-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 修飾されたviii因子
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
WO2005114221A2 (en) * 2004-05-21 2005-12-01 The Institute For Systems Biology Compositions and methods for quantification of serum glycoproteins
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
US7673687B2 (en) 2007-12-05 2010-03-09 Halliburton Energy Services, Inc. Cement compositions comprising crystalline organic materials and methods of using same
DE202007017320U1 (de) 2007-12-07 2008-02-28 Dittmann, Ludwig Vorrichtung zur Raumbeduftung
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
US20110081362A1 (en) 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
US20100168018A1 (en) 2008-11-07 2010-07-01 Baxter International Inc. Factor viii formulations

Also Published As

Publication number Publication date
SG189914A1 (en) 2013-06-28
DK2632479T3 (en) 2017-08-07
EA034494B1 (ru) 2020-02-13
US20120135019A1 (en) 2012-05-31
EP2632479B1 (en) 2017-06-14
JP2014505014A (ja) 2014-02-27
AU2016202155A1 (en) 2016-04-28
KR102222864B1 (ko) 2021-03-04
TW201231065A (en) 2012-08-01
TW201730205A (zh) 2017-09-01
CN103298482B (zh) 2015-08-19
ES2639039T3 (es) 2017-10-25
KR102040867B1 (ko) 2019-11-07
PL2632479T3 (pl) 2017-09-29
CN103298482A (zh) 2013-09-11
AR083586A1 (es) 2013-03-06
AU2011319747B2 (en) 2016-01-07
US20170267743A1 (en) 2017-09-21
CA2815239C (en) 2019-02-26
AU2011319747A1 (en) 2013-05-02
WO2012058480A1 (en) 2012-05-03
CA2815239A1 (en) 2012-05-03
EP2632479A1 (en) 2013-09-04
US9512198B2 (en) 2016-12-06
TWI580430B (zh) 2017-05-01
MX2013004753A (es) 2013-09-13
EP3260132A1 (en) 2017-12-27
BR112013010362A2 (pt) 2016-08-02
NZ609474A (en) 2015-06-26
CN104926947A (zh) 2015-09-23
EP3260132B1 (en) 2022-02-09
SG10201600656WA (en) 2016-02-26
US20150203567A1 (en) 2015-07-23
HK1215442A1 (zh) 2016-08-26
MX347805B (es) 2017-05-15
KR20130128404A (ko) 2013-11-26
JP6122780B2 (ja) 2017-04-26
TW201708251A (zh) 2017-03-01
JP2017095463A (ja) 2017-06-01
NZ703514A (en) 2017-02-24
US8969524B2 (en) 2015-03-03
AU2016202155B2 (en) 2018-02-01
PL3260132T3 (pl) 2022-08-08
AU2011319747C1 (en) 2016-07-14
KR20190126189A (ko) 2019-11-08
EA201390617A1 (ru) 2013-10-30
ES2912455T3 (es) 2022-05-26

Similar Documents

Publication Publication Date Title
SG10201600656WA (en) FVIII Peptides For Immune Tolerance Induction And Immunodiagnostics
EP2661442A4 (en) MONOMER AND MULTIMERS IMMUNOGENIC PEPTIDES
EP2521564A4 (en) APOE PEPTIDE DIMERS AND USES THEREOF
GB201012651D0 (en) Peptides
PL2588491T3 (pl) Nowy peptyd i jego zastosowanie
SG11201500111VA (en) Peptides and uses thereof
EP2593595A4 (en) NOVEL PEPTIDES AND USES THEREOF
PH12013501348A1 (en) Enhanced immune response in bovine species
EP2605786A4 (en) THERAPEUTIC PEPTIDES
GB201005931D0 (en) Immune modulation
EP2914293A4 (en) METHOD OF USE OF FVIII POLYPEPTIDE
PL2627668T3 (pl) Peptydy i ich zastosowanie
HUE040630T2 (hu) Többfázisú konverter mágnesesen csatolt fázisokkal
GB201016494D0 (en) Polypeptide
EP2624856A4 (en) MOESINFRAGMENTS WITH IMMUNO THROMBO CYTOPENIA
IL235835B (en) A new antigenic peptide from melanoma and its uses
ZA201303886B (en) Tomm34 peptides and vaccines including the same
IL221474A0 (en) Hjurp peptides and vaccines including the same
GB201014404D0 (en) Removable induction stovetop cover
GB0917685D0 (en) Antigenic polypeptide
PL2383755T3 (pl) Element indukcyjny
IL235836B (en) Melanoma antigenic peptide and its uses
EP2771689A4 (en) PEPTIDES USP2A AND ANTIBODIES
IL225552A0 (en) wdhd1 peptides and vaccines containing them
IL225553A0 (en) 54orf18c peptides and vaccines containing them